Zhejiang Wecome Pharmaceutical (300878.SZ) announced its performance for the first half of the year, with a net income of 14.1921 million yuan, a decrease of 78.04%.

Zhejiang Wecome Pharmaceutical (300878.SZ) released its semi-annual report for 2024, with a revenue of 0.297 billion...

Zhejiang Wecome Pharmaceutical (300878.SZ) released its semi-annual report for 2024, with a revenue of 0.297 billion yuan, a decrease of 6.15% compared to the previous year. The net income attributable to shareholders of the listed company was 14.1921 million yuan, a decrease of 78.04% compared to the previous year. The net income attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 8.4231 million yuan, a decrease of 85.28% compared to the previous year. The basic earnings per share was 0.1 yuan.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

维康药业(300878.SZ)发布上半年业绩，净利润1419.21万元，下降78.04%

Zhejiang Wecome Pharmaceutical (300878.SZ) announced its performance for the first half of the year, with a net income of 14.1921 million yuan, a decrease of 78.04%.

Risk Disclaimer

Statement